Concepts (225)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 42 | 2022 | 3110 | 2.540 |
Why?
|
| Thyroid Neoplasms | 14 | 2021 | 442 | 2.240 |
Why?
|
| Carcinoma, Ductal, Breast | 11 | 2019 | 165 | 1.770 |
Why?
|
| Mastectomy | 19 | 2022 | 262 | 1.680 |
Why?
|
| Lymph Nodes | 13 | 2018 | 548 | 1.560 |
Why?
|
| Sentinel Lymph Node Biopsy | 10 | 2018 | 86 | 1.540 |
Why?
|
| Thyroidectomy | 11 | 2021 | 173 | 1.520 |
Why?
|
| Lymph Node Excision | 10 | 2018 | 233 | 1.500 |
Why?
|
| Carcinoma, Lobular | 10 | 2019 | 84 | 1.460 |
Why?
|
| Carcinoma, Papillary | 8 | 2020 | 159 | 1.330 |
Why?
|
| Mastectomy, Segmental | 8 | 2017 | 107 | 1.320 |
Why?
|
| Adrenocortical Carcinoma | 4 | 2022 | 15 | 1.160 |
Why?
|
| Adrenal Cortex Neoplasms | 4 | 2022 | 21 | 1.160 |
Why?
|
| Iodine Radioisotopes | 6 | 2021 | 137 | 1.160 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 5 | 2016 | 122 | 1.090 |
Why?
|
| Carcinoma | 5 | 2017 | 439 | 0.970 |
Why?
|
| Lymphatic Metastasis | 16 | 2020 | 504 | 0.860 |
Why?
|
| Parathyroidectomy | 3 | 2020 | 79 | 0.840 |
Why?
|
| Hyperparathyroidism, Primary | 3 | 2020 | 46 | 0.730 |
Why?
|
| Databases, Factual | 18 | 2020 | 1006 | 0.720 |
Why?
|
| Neoplasm Staging | 20 | 2021 | 2017 | 0.690 |
Why?
|
| Radiopharmaceuticals | 4 | 2016 | 203 | 0.670 |
Why?
|
| Axilla | 13 | 2018 | 109 | 0.620 |
Why?
|
| Middle Aged | 57 | 2021 | 27573 | 0.590 |
Why?
|
| Hypercalcemia | 1 | 2018 | 60 | 0.560 |
Why?
|
| Radiotherapy, Adjuvant | 9 | 2021 | 314 | 0.540 |
Why?
|
| Female | 68 | 2022 | 48702 | 0.540 |
Why?
|
| Aged | 47 | 2021 | 20434 | 0.540 |
Why?
|
| Thyroid Gland | 6 | 2021 | 280 | 0.510 |
Why?
|
| Pancreatic Neoplasms | 6 | 2018 | 715 | 0.510 |
Why?
|
| Guideline Adherence | 2 | 2017 | 236 | 0.510 |
Why?
|
| Neoadjuvant Therapy | 5 | 2019 | 446 | 0.450 |
Why?
|
| Retrospective Studies | 27 | 2022 | 10164 | 0.450 |
Why?
|
| Humans | 75 | 2022 | 93515 | 0.440 |
Why?
|
| Prognosis | 21 | 2019 | 3911 | 0.430 |
Why?
|
| Aged, 80 and over | 20 | 2021 | 7061 | 0.420 |
Why?
|
| Surgeons | 3 | 2022 | 292 | 0.370 |
Why?
|
| Adult | 33 | 2021 | 27918 | 0.360 |
Why?
|
| Carcinoma, Pancreatic Ductal | 3 | 2018 | 131 | 0.360 |
Why?
|
| Combined Modality Therapy | 7 | 2022 | 1723 | 0.340 |
Why?
|
| United States | 21 | 2022 | 7622 | 0.320 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2015 | 624 | 0.300 |
Why?
|
| Receptors, Estrogen | 5 | 2019 | 413 | 0.300 |
Why?
|
| Adenocarcinoma | 4 | 2016 | 1173 | 0.300 |
Why?
|
| Follow-Up Studies | 16 | 2021 | 3830 | 0.300 |
Why?
|
| Survival Rate | 13 | 2020 | 1948 | 0.300 |
Why?
|
| Logistic Models | 6 | 2020 | 1243 | 0.290 |
Why?
|
| Neck Dissection | 2 | 2021 | 67 | 0.280 |
Why?
|
| Pancreaticoduodenectomy | 3 | 2017 | 92 | 0.280 |
Why?
|
| Practice Guidelines as Topic | 5 | 2019 | 1053 | 0.280 |
Why?
|
| Nipples | 5 | 2022 | 37 | 0.270 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2021 | 1448 | 0.260 |
Why?
|
| Chemotherapy, Adjuvant | 8 | 2019 | 512 | 0.250 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 3 | 2004 | 10 | 0.250 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2019 | 283 | 0.240 |
Why?
|
| Male | 27 | 2021 | 44557 | 0.240 |
Why?
|
| Ergonomics | 3 | 2022 | 25 | 0.240 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2017 | 152 | 0.230 |
Why?
|
| Treatment Outcome | 10 | 2021 | 9099 | 0.220 |
Why?
|
| Age Factors | 8 | 2021 | 1906 | 0.220 |
Why?
|
| Melanoma | 1 | 2009 | 495 | 0.210 |
Why?
|
| Length of Stay | 4 | 2022 | 828 | 0.210 |
Why?
|
| Patient Selection | 3 | 2013 | 690 | 0.210 |
Why?
|
| Neoplasm Invasiveness | 6 | 2020 | 572 | 0.210 |
Why?
|
| Skin Neoplasms | 1 | 2009 | 620 | 0.200 |
Why?
|
| Biopsy, Needle | 2 | 2003 | 225 | 0.200 |
Why?
|
| Biomarkers, Tumor | 4 | 2019 | 1660 | 0.200 |
Why?
|
| Risk Factors | 7 | 2021 | 5899 | 0.190 |
Why?
|
| Brachytherapy | 2 | 2014 | 126 | 0.190 |
Why?
|
| Mastectomy, Subcutaneous | 1 | 2022 | 8 | 0.180 |
Why?
|
| Surgical Oncology | 2 | 2020 | 29 | 0.180 |
Why?
|
| Precancerous Conditions | 1 | 2003 | 205 | 0.180 |
Why?
|
| Hospitals, High-Volume | 1 | 2022 | 43 | 0.170 |
Why?
|
| Breast | 1 | 2003 | 294 | 0.170 |
Why?
|
| Receptors, Progesterone | 2 | 2019 | 196 | 0.170 |
Why?
|
| Adrenalectomy | 2 | 2018 | 44 | 0.170 |
Why?
|
| Proportional Hazards Models | 7 | 2017 | 889 | 0.160 |
Why?
|
| Time Factors | 5 | 2021 | 5410 | 0.160 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2017 | 920 | 0.160 |
Why?
|
| Mammaplasty | 1 | 2022 | 122 | 0.160 |
Why?
|
| Survival Analysis | 4 | 2017 | 1524 | 0.160 |
Why?
|
| Thyroid Epithelial Cells | 1 | 2020 | 6 | 0.160 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2020 | 37 | 0.150 |
Why?
|
| Medical Overuse | 1 | 2019 | 30 | 0.150 |
Why?
|
| Pancreatectomy | 2 | 2017 | 168 | 0.150 |
Why?
|
| Organ Sparing Treatments | 1 | 2019 | 47 | 0.150 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2019 | 2544 | 0.150 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2021 | 876 | 0.140 |
Why?
|
| Thoracic Wall | 1 | 2018 | 26 | 0.140 |
Why?
|
| Biopsy | 2 | 2017 | 1175 | 0.140 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 2018 | 57 | 0.130 |
Why?
|
| Mesenteric Veins | 1 | 2017 | 36 | 0.130 |
Why?
|
| Receptor, ErbB-2 | 1 | 2019 | 280 | 0.130 |
Why?
|
| Radiation Oncology | 1 | 2019 | 124 | 0.130 |
Why?
|
| Chromosome Aberrations | 1 | 2018 | 350 | 0.130 |
Why?
|
| Prophylactic Mastectomy | 1 | 2016 | 13 | 0.120 |
Why?
|
| Young Adult | 8 | 2021 | 6930 | 0.120 |
Why?
|
| Vascular Surgical Procedures | 1 | 2017 | 150 | 0.120 |
Why?
|
| Hepatectomy | 1 | 2017 | 177 | 0.120 |
Why?
|
| Neoplasm Grading | 5 | 2016 | 402 | 0.120 |
Why?
|
| Laparoscopy | 3 | 2018 | 782 | 0.120 |
Why?
|
| Quality Improvement | 1 | 2020 | 485 | 0.120 |
Why?
|
| Chromatin | 1 | 2018 | 440 | 0.110 |
Why?
|
| Mammography | 3 | 2017 | 458 | 0.110 |
Why?
|
| Societies, Medical | 1 | 2019 | 621 | 0.110 |
Why?
|
| Risk | 1 | 2016 | 657 | 0.110 |
Why?
|
| Parathyroid Neoplasms | 1 | 2015 | 60 | 0.110 |
Why?
|
| Decision Support Techniques | 1 | 2016 | 185 | 0.110 |
Why?
|
| Epigenesis, Genetic | 1 | 2018 | 555 | 0.100 |
Why?
|
| Quality of Health Care | 1 | 2017 | 382 | 0.100 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2016 | 283 | 0.100 |
Why?
|
| Prospective Studies | 8 | 2021 | 4560 | 0.100 |
Why?
|
| Propensity Score | 3 | 2021 | 178 | 0.100 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2017 | 418 | 0.100 |
Why?
|
| Genes, BRCA2 | 1 | 2014 | 162 | 0.100 |
Why?
|
| Disease-Free Survival | 2 | 2011 | 1170 | 0.100 |
Why?
|
| Genes, BRCA1 | 1 | 2014 | 191 | 0.100 |
Why?
|
| Patient Education as Topic | 1 | 2016 | 373 | 0.100 |
Why?
|
| Neoplasms, Second Primary | 1 | 2015 | 245 | 0.100 |
Why?
|
| Patient Satisfaction | 1 | 2016 | 484 | 0.100 |
Why?
|
| Thyroid Diseases | 1 | 2013 | 106 | 0.100 |
Why?
|
| Time-to-Treatment | 1 | 2014 | 140 | 0.090 |
Why?
|
| Liver | 1 | 2017 | 1210 | 0.090 |
Why?
|
| Estrogen Receptor alpha | 1 | 2013 | 155 | 0.090 |
Why?
|
| Contraindications | 1 | 2012 | 67 | 0.090 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2013 | 188 | 0.090 |
Why?
|
| Multivariate Analysis | 4 | 2017 | 985 | 0.090 |
Why?
|
| Adolescent | 7 | 2021 | 9606 | 0.090 |
Why?
|
| Liver Neoplasms | 1 | 2017 | 776 | 0.080 |
Why?
|
| Workload | 2 | 2022 | 126 | 0.080 |
Why?
|
| Operating Rooms | 2 | 2022 | 137 | 0.080 |
Why?
|
| Liver Transplantation | 1 | 2017 | 1194 | 0.080 |
Why?
|
| SEER Program | 3 | 2015 | 235 | 0.070 |
Why?
|
| Predictive Value of Tests | 3 | 2018 | 1713 | 0.070 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2009 | 48 | 0.070 |
Why?
|
| Radionuclide Imaging | 4 | 2004 | 189 | 0.070 |
Why?
|
| Interferon-alpha | 1 | 2009 | 187 | 0.070 |
Why?
|
| Margins of Excision | 2 | 2018 | 45 | 0.070 |
Why?
|
| Immunologic Factors | 1 | 2009 | 176 | 0.070 |
Why?
|
| Cancer Vaccines | 1 | 2009 | 167 | 0.070 |
Why?
|
| Cohort Studies | 3 | 2021 | 3054 | 0.070 |
Why?
|
| Tumor Burden | 2 | 2021 | 321 | 0.070 |
Why?
|
| Pilot Projects | 3 | 2019 | 917 | 0.060 |
Why?
|
| Chromosome Mapping | 1 | 2009 | 1052 | 0.060 |
Why?
|
| Reoperation | 2 | 2021 | 702 | 0.060 |
Why?
|
| Sequence Analysis, DNA | 1 | 2009 | 893 | 0.060 |
Why?
|
| Early Diagnosis | 1 | 2006 | 135 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 3476 | 0.060 |
Why?
|
| Genome, Human | 1 | 2009 | 823 | 0.050 |
Why?
|
| Hyperplasia | 1 | 2003 | 147 | 0.050 |
Why?
|
| Patient Readmission | 2 | 2017 | 412 | 0.050 |
Why?
|
| Radiotherapy Dosage | 2 | 2014 | 472 | 0.050 |
Why?
|
| Medically Uninsured | 1 | 2022 | 67 | 0.050 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2003 | 116 | 0.040 |
Why?
|
| Sensitivity and Specificity | 3 | 2018 | 1922 | 0.040 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2021 | 49 | 0.040 |
Why?
|
| Algorithms | 1 | 2009 | 1953 | 0.040 |
Why?
|
| Insurance Coverage | 1 | 2022 | 142 | 0.040 |
Why?
|
| Mass Screening | 1 | 2006 | 696 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2020 | 81 | 0.040 |
Why?
|
| Hernia, Inguinal | 1 | 2020 | 75 | 0.040 |
Why?
|
| Herniorrhaphy | 1 | 2020 | 91 | 0.040 |
Why?
|
| Neoplasm Micrometastasis | 1 | 2018 | 7 | 0.030 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2018 | 107 | 0.030 |
Why?
|
| Conversion to Open Surgery | 1 | 2018 | 11 | 0.030 |
Why?
|
| Thyroid Nodule | 1 | 2018 | 60 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 291 | 0.030 |
Why?
|
| Hematoxylin | 1 | 1997 | 8 | 0.030 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 1997 | 13 | 0.030 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2018 | 39 | 0.030 |
Why?
|
| Keratins | 1 | 1997 | 62 | 0.030 |
Why?
|
| Coloring Agents | 1 | 1997 | 65 | 0.030 |
Why?
|
| Postoperative Hemorrhage | 1 | 2017 | 49 | 0.030 |
Why?
|
| Nucleic Acid Conformation | 1 | 2018 | 342 | 0.030 |
Why?
|
| Operative Time | 1 | 2017 | 167 | 0.030 |
Why?
|
| Blood Loss, Surgical | 1 | 2017 | 131 | 0.030 |
Why?
|
| Healthcare Disparities | 1 | 2022 | 486 | 0.030 |
Why?
|
| Shock, Septic | 1 | 2017 | 124 | 0.030 |
Why?
|
| Ultrasonography, Mammary | 1 | 2017 | 82 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 2017 | 175 | 0.030 |
Why?
|
| Medical Oncology | 1 | 2020 | 404 | 0.030 |
Why?
|
| Prevalence | 1 | 2020 | 1321 | 0.030 |
Why?
|
| Self Report | 1 | 2016 | 328 | 0.030 |
Why?
|
| Selection Bias | 1 | 2014 | 37 | 0.030 |
Why?
|
| Chemoradiotherapy | 1 | 2017 | 326 | 0.030 |
Why?
|
| Decision Making | 1 | 2019 | 674 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2015 | 196 | 0.030 |
Why?
|
| Hospitals, Public | 1 | 2013 | 15 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 1518 | 0.020 |
Why?
|
| Heterozygote | 1 | 2014 | 382 | 0.020 |
Why?
|
| Age Distribution | 1 | 2013 | 206 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 1997 | 1799 | 0.020 |
Why?
|
| Insurance, Health | 1 | 2014 | 179 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2017 | 1061 | 0.020 |
Why?
|
| Urban Population | 1 | 2013 | 234 | 0.020 |
Why?
|
| Registries | 1 | 2017 | 990 | 0.020 |
Why?
|
| Sex Factors | 1 | 2015 | 1105 | 0.020 |
Why?
|
| Illinois | 1 | 2013 | 520 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 1917 | 0.020 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2000 | 1133 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2014 | 375 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 2715 | 0.020 |
Why?
|
| Hospitals | 1 | 2013 | 328 | 0.020 |
Why?
|
| General Surgery | 1 | 2013 | 248 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2014 | 481 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2017 | 2441 | 0.020 |
Why?
|
| Expressed Sequence Tags | 1 | 2009 | 34 | 0.020 |
Why?
|
| Postmenopause | 1 | 2009 | 106 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2000 | 2365 | 0.020 |
Why?
|
| Quality of Life | 1 | 2016 | 1780 | 0.020 |
Why?
|
| Palpation | 1 | 2006 | 19 | 0.020 |
Why?
|
| Community Health Services | 1 | 2006 | 81 | 0.010 |
Why?
|
| Mutation | 1 | 2014 | 4272 | 0.010 |
Why?
|
| Ranitidine | 1 | 2000 | 8 | 0.010 |
Why?
|
| Intraoperative Period | 1 | 2000 | 94 | 0.010 |
Why?
|
| Premedication | 1 | 2000 | 57 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2000 | 278 | 0.010 |
Why?
|
| Physical Examination | 1 | 2000 | 144 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2000 | 284 | 0.010 |
Why?
|
| Fluorouracil | 1 | 2000 | 524 | 0.010 |
Why?
|
| Dexamethasone | 1 | 2000 | 312 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2000 | 479 | 0.010 |
Why?
|
| Remission Induction | 1 | 2000 | 738 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2000 | 756 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2000 | 702 | 0.010 |
Why?
|